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We herein report the clinicopathologic features of a rare case of biliary adenoﬁbroma (BAF) of the liver in a 79-year-old man.
Grossly,tumourpresentedasawell-circumscribed,5.5-cmmasswithasolidandmicrocysticappearance.Histologicalexamination
was typical of biliary adenoﬁbroma, showing a proliferation of variable-sized tubulocystic structures embedded in a moderately
cellular ﬁbrous stroma. Immunohistochemistry, revealing immunoreactivity of the epithelial component to cytokeratins 7 and
19, was consistent with a bile duct origin. Notably, the stromal cells had a myoﬁbroblastic proﬁle, showing a diﬀuse and strong
expression of vimentin and α-smooth muscle actin. Diﬀerential diagnosis with Von Meyenburg complex, biliary adenoma, biliary
cistadenoma,congenitalbiliarycystsy,andhepaticbenigncysticmesotheliomaisprovided.Theoccasionallyreportedexpressionof
p53 in biliary adenoﬁbroma has suggested that this tumour could represent a premalignant lesion. The absence of both cytological
atypia and p53 immunoreactivity in our case conﬁrms that BAF is a benign tumour with an indolent clinical behaviour. However,
a careful histological examination of BAF is mandatory because malignant transformation of the epithelial component has been
documented in two cases.
1.Introduction
Benign biliary tumours are uncommon, including bile
duct adenoma (also known as peribiliary gland hamar-
toma),biliaryhamartoma(vonMeyenburgcomplex),biliary
cystadenoma, and the solitary bile cysts. Tsui et al. in
1993 described a new liver tumour entity called “biliary
adenoﬁbroma” (BAF) [1]. To the best of our knowledge,
only six cases of BAF of the liver have been reported in
the literature to date (Table 1)[ 1–6]. Two of us reported
a morphologically similar tumour in equine [7]. BAF is
characterized by a proliferation of tubulocystic structures
variably embedded in a ﬁbrous stroma. Etiology of BAF
is still unknown, even if its immunophenotypic proﬁle
(cytokeratins 7+,8 +,1 8 +,1 9 +,D 1 0 +,1 F 6 −) suggests a large
bile and/or interlobular duct origin [6]. Interestingly, mono-
somy 22, a cytogenetic alteration found in some benign
mesenchymal neoplasms, has been documented in one case
of BAF [5]. Although BAF is a benign tumour with a clinical
indolentbehavior,malignanttransformationoftheepithelial
component [2, 3] with associated distant metastases [3]h a s
been documented.
Wehereinreporttheclinicopathologicalfeaturesofarare
case of liver BAF with a benign clinical course after a 7-year
follow-up period. Diﬀerential diagnostic and histogenetic
considerations are discussed.
2. ClinicalHistory
A 79-year-old man complained of a vague abdominal pain.
Ultrasound examination and computerized tomography
revealed a solid 5.5cm mass in the right lobe of liver. Blood
tests, including alpha-fetoprotein, were unremarkable. No
lymphadenopathy was present. A partial liver resection was
performed. No postoperative complications were noted. The
patient is well with no recurrence after a 7-year follow-up
period.2 Pathology Research International
Table 1: Clinical features of BAFs reported in the literature.
Authors n. cases Age/gender Size Malignant
component Behaviour
Tsui et al. [1] 1 74/female 7cm No No recurrence or metastasis
Parada et al. [5] 1 49/female 7.5cm No No recurrence or metastasis
Haberal et al. [2] 1 21/male 20cm Yes (epithelial) N.A
Garduno-Lopez et al. [4] 1 68/male 6cm No N.A
Akin and Coskun [3] 1 25/male 20cm Yes (epithelial) Recurrence and pulmonary metastasis
after a 3-year followup
Varnholt et al. [6] 1 47/female 16cm No No recurrence or metastasis
after a 3-year followup
Gurrera et al. (present case) 1 79/male 5.5cm No No recurrence or metastasis
after a 7-year followup
Not available.
Table 2: Immunohistochemical ﬁndings.
Antibodies Dilution and company Results (Epithelial component) Results (Stromal component)
Cytokeratin AE1/AE3 1/100 (DakoCytomation) Positive Negative
CK7 1/50 (Novocastra) Positive Negative
Cytokeratin 8/18 (CAM5.2) 1/100 (DakoCytomation) Positive Negative
CK19 1/50 (Novocastra) Positive Negative
EMA 1/200 (DakoCytomation) Positive Negative
CEA prediluted (DakoCytomation) Negative Negative
P53 1/50 (DakoCytomation) Negative Negative
Ki-67 1/200 (DakoCytomation) Positive (1%) Positive (1%)
Vimentin 1/50 (DakoCytomation) Negative Positive
α-smooth muscle actin 1/50 (DakoCytomation) Negative Positive
Desmin 1/100 (DakoCytomation) Negative Negative
Calretinin 1/100 (DakoCytomation) Negative Negative
HBME-1 1/100 (DakoCytomation) Negative Negative
Beta-catenin 1/200 (Novocastra) Negative Negative
3.MaterialsandMethods
Surgical specimen was submitted for histological examina-
tion in neutral-buﬀered 10% formalin, dehydrated using
standard techniques, embedded in paraﬃn, cut to 5μm, and
stained with hematoxylin and eosin. Immunohistochemical
studies were performed with the labeled streptavidin-biotin
peroxidase detection system using the Ventana automated
immunostainer (Ventana Medical Systems, Tucson, AZ).
The antibodies tested are summarized in Table 2.N e g a t i v e
controls for the staining were slides stained with omission of
the primary antibody.
4.Pathological Findings
Grossly, surgical specimen consisted of liver parenchyma
(14×10×4cm) containing a 5.5-cm nodular mass merging
from the liver capsule. The cut surface of the mass showed
an unencapsulated, well-circumscribed, and ﬁrm lesion with
a solid and microcystic appearance. Cysts ranged in size
from 0.1 to 0.5cm. Histologically, at low magniﬁcation,
the tumour was composed of a proliferation of nonmucin-
secreting, tubulocystic structures, embedded in a moderately
cellular ﬁbrous stroma (Figure 1). Both tubules and cysts
were lined by a single layer of cuboidal to ﬂat, bile duct-
type epithelium (Figure 2). Lumens of the tubulocystic
structures contained eosinophilic material and/or red blood
cells, while bile was absent. Nuclei were round to oval in
shape and centrally located. No goblet cells were observed. In
some areas, the epithelium formed papillary projections into
the lumens. Necrosis, mitoses, and nuclear pleomorphism
were absent. Stromal component contained spindle-shaped
ﬁbroblast-like cells and scattered lymphocytes (Figures 1
and 2). Islands of hepatic parenchyma were seen scattered
throughout the tumour (Figure 3).
Immunohistochemically (Table 2), the epithelial compo-
nent was stained with cytokeratins 7, 8, 18, and 19 (Figure 4)
and epithelial membrane antigen (EMA).Carcinoembryonic
antigen (CEA), cytokeratins 5/6, p53, calretinin, HBME-1,
and beta-catenin were negative. Ki-67/index proliferation
was low (1%). The stromal cells were strongly and diﬀusely
stained with vimentin and α-smooth muscle actin (Figure
5) while no immunoreactivity was detected for desmin.
Based on their morphological and immunohistochemical
proﬁle, these cells were regarded to be myoﬁbroblastic in
nature.Pathology Research International 3
Figure 1: Low magniﬁcation showing a proliferation of variable-
sized tubulocystic epithelial structures embedded in a ﬁbrous
stroma.
Figure 2: Tubules are lined by bile duct epithelium and set in a
moderately ﬁbrous stroma.
5. Discussion
BAF is a rare tumour of bile duct origin with only six
cases reported in the literature to date [1–6]( Table 1). BAF
is equally reported both in women and men ranging in
a g ef r o m2 1t o7 9y e a r s( Table 1). Most patients complain
of abdominal pain in the right hypochondrium. Imaging
studies, including ultrasonography, computerized tomogra-
phy and magnetic resonance imaging, usually reveal a well-
circumscribed solid-cystic mass, variable in size from 5.5 to
20cm (Table 1). Unfortunately, radiologic images, including
Figure 3: Residual hepatocytes are entrapped within tumour.
Figure 4: Tubules of tumour are positive for cytokeratin 19.
those of our case, are nonspeciﬁc, and the diagnosis of BAF
of the liver is based on histological examination [2–4, 6].
The present case has the morphological characteristic
and immunohistochemical features of liver BAF. Grossly,
tumourpresentedasanunencapsulated,well-circumscribed,
5.5cmsolid-cysticnodule.Histologically,itwascomposedof
a tubulocystic proliferation of variable-sized bile ducts with
an immunohistochemical proﬁle (CK7+ ,C K 1 9 +) suggesting
ab i l ed u c to r i g i n[ 1, 6]. The lumens of the tubules contained
eosinophilic material and/or red blood cells but bile was
absent [1, 6]. The epithelial component was embedded in4 Pathology Research International
Figure 5: Stromal cells are strongly and diﬀusely stained with α-
smooth muscle actin, revealing their myoﬁbroblastic nature.
a moderately cellular ﬁbrous stroma, predominantly con-
tainingmyoﬁbroblastsasdocumentedbyadiﬀuseandstrong
immunoreactivity for α-smooth muscle actin. Notably, the
cellular stromal component of liver BAF has been reported
to be ﬁbroblastic rather than myoﬁbroblastic in nature,
because only scattered α-smooth muscle actin+ cells have
been identiﬁed [6]. As beta-catenin has been reported
to be expressed in some tumours with adenoﬁbromatous
components [8], we evaluated this marker in the present case
of BAF. Unfortunately, we found no immunoreactivity for
this antigen either in the epithelial or stromal component.
Diﬀerential diagnosis of BAF includes von Meyenburg
complex, bile duct adenoma, biliary cystadenoma, bil-
iary cysts, and benign cystic mesothelioma. BAF generally
presents as a large-sized nodule with a solid microcys-
tic appearance, whereas von Meyenburg complex can be
incidentally found either as single or multiple subcapsular
nodules of small size, usually less than 5mm in diameter [9].
This complex may represent part of the spectrum of ductal
plate malformation and may be related to adult type poly-
cystic disease [9]. Histologically, von Meyenburg complex is
located within or adjacently to portal tracts and it is com-
posed of multiple-branched bile ducts, sometimes with an
angulated appearance, set in a collagenous stroma [9]. These
tubular structures contain bile and/or eosinophilic material
[9]. Bile duct adenoma is generally a well-demarcated, small-
sized lesion with a diameter ≤1cm, usually located directly
underneath the liver capsule. Occasionally, this lesion may
present as two or more nodules with a maximal diameter
of 2cm. Histologically, it is characterized by closely packed
tubules with narrow lumens, lined by cuboidal bile-type
epithelium, set in an edematous to dense ﬁbrous stroma
which may contain a variable amount of inﬂammatory cells.
Unlike BAF, these tubules show more irregular outlines and
less cystic conﬁguration while stromal component is less
prominent. Bile duct adenoma is not a true neoplasm but it
is currently regarded as a peribiliary gland hamartoma [10]
or a localized reactive ductular proliferation as result of a
previous unknown injury. Unlike BAF, biliary (peribiliary)
cystadenoma is a large-sized cystic tumour with multilocular
appearance, in which cysts may be up to 15cm of diam-
eter. Two histological variants were recognized: serous and
mucinous types [9]. The former consists of small cysts lined
by a single layer of low cuboidal or ﬂat epithelium with a
clear cytoplasm; the latter contains cysts lined by columnar,
cuboidal or ﬂattened mucous-secreting epithelial cells with
occasionallypapillaryprojectionsandanovarian-likestroma
appearance, especially if the lesion occurs in women [11],
with a characteristic immunoreactivity for oestrogen and
progesterone receptors [12, 13]. The congenital biliary cysts
(simple cysts) are lined by bile duct-type epithelium, and
they may be solitary or multiple; the multiple form may
be part of the polycystic disease. In our case, according to
reported cases in the literature, no polycystic disease in the
liver and in other organs was noted. Among the biliary
cystic lesions of the liver the benign cystic mesothelioma
can also be included, a rare neoplasm which may occur in
the liver [14]. It is a large, partially cystic, well-encapsulated
lesion, characterized by anastomosing cords of tumour cells,
separated by large thick-walled vessels, closely reminiscent
of a vascular neoplasm. This morphological pattern is quite
diﬀerentfromthatexhibitedbythetumourhereinpresented.
In addition, neoplastic cells of benign cystic mesothelioma
arepositivetocalretinin,HBME-1,andcytokeratins5/6[14].
As far histogenesis of BAF is concerned, it is noteworthy
that histological features similar to BAF and von Meyenburg
complex have been obtained in animal-model of aﬂatoxin-
induced cholangiocarcinoma [15]. These experimental ﬁnd-
ings, along with the large size, the p53 expression, and the
tetraploidy status with a low S-phase being occasionally
reported, strongly suggest that BAF could represent a prema-
lignant lesion [6]. This hypothesis seems to be supported by
the evidence that two cases of liver BAF underwent epithelial
malignant transformation [2, 3]. However, in our case, we
did not ﬁnd any immunoreactivity for p53, conﬁrming
that BAF should be regarded as a benign tumour. Despite
the absence of cytological atypia and p53 positivity, we
emphasize that any BAF should be carefully evaluated to rule
out malignancy.
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